Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALXO 
Alx Oncology Holdings (ALXO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ALXO (3-star) is a STRONG-BUY. BUY since 36 days. Simulated Profits (71.43%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $2.25
1 Year Target Price $2.25
| 3 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 70.64% | Avg. Invested days 29 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.76M USD | Price to earnings Ratio - | 1Y Target Price 2.25 |
Price to earnings Ratio - | 1Y Target Price 2.25 | ||
Volume (30-day avg) 6 | Beta 1.12 | 52 Weeks Range 0.40 - 2.26 | Updated Date 09/16/2025 |
52 Weeks Range 0.40 - 2.26 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.14 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -47.78% | Return on Equity (TTM) -104.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -12509798 | Price to Sales(TTM) 5906.24 |
Enterprise Value -12509798 | Price to Sales(TTM) 5906.24 | ||
Enterprise Value to Revenue 4254.36 | Enterprise Value to EBITDA -2.35 | Shares Outstanding 53551100 | Shares Floating 31604273 |
Shares Outstanding 53551100 | Shares Floating 31604273 | ||
Percent Insiders 2.58 | Percent Institutions 68.45 |
Upturn AI SWOT
Alx Oncology Holdings
Company Overview
History and Background
ALX Oncology was founded in 2015 and is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway. They aim to overcome CD47-mediated immune evasion, a mechanism used by cancer cells to avoid detection and destruction by the immune system.
Core Business Areas
- CD47 Checkpoint Inhibition: ALX Oncology's primary focus is developing therapies that target the CD47 checkpoint pathway to enhance anti-cancer immune responses.
- Immuno-Oncology Research and Development: The company conducts research and development activities to discover and develop novel immuno-oncology therapies.
Leadership and Structure
Jaume Pons is the President and CEO. The company has a board of directors and a management team focused on research, development, and clinical operations.
Top Products and Market Share
Key Offerings
- Evorpacept (ALX148): Evorpacept is ALX Oncology's lead product candidate, a CD47 blocking fusion protein designed to enhance the activity of anti-cancer antibodies. It is currently in clinical development for various hematologic and solid malignancies. Market share data is not publicly available as the product is still in clinical trials. Key competitors targeting CD47 include Gilead (Magrolimab) and Arch Oncology (AO-176).
Market Dynamics
Industry Overview
The immuno-oncology market is rapidly growing, driven by advancements in understanding the role of the immune system in cancer. Checkpoint inhibitors, including CD47-targeting therapies, are a significant area of focus.
Positioning
ALX Oncology is positioned as a key player in the CD47 checkpoint inhibition space, focusing on developing differentiated therapies with improved safety and efficacy profiles compared to existing approaches. They are in clinical trials to demonstrate their competitive advantage.
Total Addressable Market (TAM)
The total addressable market for immuno-oncology is estimated to be in the tens of billions of dollars and is expected to grow significantly. ALX Oncology is aiming to capture a portion of this market by developing effective CD47 inhibitors for a range of cancers.
Upturn SWOT Analysis
Strengths
- Novel CD47 blocking technology
- Focus on differentiated therapies with improved safety profiles
- Experienced management team
- Strong intellectual property position
Weaknesses
- Single lead product candidate (Evorpacept)
- Reliance on clinical trial success
- Intense competition in the immuno-oncology space
- High cash burn rate typical of biotech companies
Opportunities
- Expansion of Evorpacept into additional cancer indications
- Potential partnerships with pharmaceutical companies
- Positive clinical trial data leading to regulatory approval
- Advancements in biomarker discovery to identify patients most likely to respond to Evorpacept
Threats
- Clinical trial failures
- Competition from other CD47 inhibitors and immuno-oncology therapies
- Regulatory hurdles and delays
- Patent challenges
Competitors and Market Share
Key Competitors
- GILD
- ARCT
Competitive Landscape
ALX Oncology aims to differentiate itself through a potentially better safety profile and efficacy compared to competitors in the CD47 space.
Growth Trajectory and Initiatives
Historical Growth: ALX Oncology's growth is tied to its clinical development progress.
Future Projections: Future growth depends on the success of Evorpacept in clinical trials and regulatory approval.
Recent Initiatives: Advancing Evorpacept through clinical trials.
Summary
ALX Oncology is a clinical-stage company with a promising CD47-blocking therapy, Evorpacept, in development. Its success hinges on positive clinical trial results and regulatory approval. It faces stiff competition in the immuno-oncology space, particularly from Gilead. A strong focus on differentiation and safety is key. It needs to carefully manage its cash burn rate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alx Oncology Holdings
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2020-07-17 | CEO & Director Mr. Jason W. Lettmann | ||
Sector Healthcare | Industry Biotechnology | Full time employees 49 | Website https://www.alxoncology.com |
Full time employees 49 | Website https://www.alxoncology.com | ||
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Symposium; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.